Broncho-Vaxom Adult, capsules 7 mg, 30 pcs.

When taken orally, Broncho-Vaxom stimulates the body’s immune defense and increases resistance to infections of the respiratory system.

Immunopharmacological studies have shown that Broncho-Vaxom shows the following effects: in humans Broncho-Vaxom: increases the formation of immunoglobulin A secreted by respiratory tract mucosa and saliva, increases the number of circulating T-lymphocytes.

In animals, Broncho-Vaxom: actively protects against infections, stimulates B-lymphocytes and macrophages. Clinically Broncho-Vaxom reduces the frequency of acute infections, reduces the duration of their course and reduces the severity of symptoms, and reduces the likelihood of exacerbations of chronic diseases.

The need for other medications, especially antibiotics, is reduced.

Indications

Prevention of recurrent respiratory tract infection and exacerbations of chronic bronchitis.

Use in the complex treatment of acute respiratory tract infections.

Active ingredient

Composition

Associates:

Propyl gallate anhydrous (E310) – 0.084 mg,

monosodium glutamate (corresponds to anhydrous sodium glutamate (sodium glutamate)) – 3.03 mg,

mannitol – the required amount up to 40 mg,

pregelatinized starch – 110 mg,

magnesium stearate – 3 mg,

mannitol – the required amount up to 200 mg.

Capsule shell composition:

indigo carmine (indigotine) (dye E132) – 0.03 mg, titanium dioxide (dye E171) – 1 mg, gelatin – required amount up to 50 mg.

How to take, the dosage

Broncho-Vaxom® Adult is indicated for adults and children 12 years of age and older.

To treat: 1 capsule of Broncho-Vaxom® Adult daily in the morning on an empty stomach until symptoms disappear, but not less than 10 days. If antibiotic therapy is necessary, Broncho-Vaxom® adult should be taken in combination with an antibiotic from the beginning of treatment.

The duration of treatment or the prescription of repeated therapy should be determined by a physician based on the patient’s health status.

For the purpose of prevention of exacerbations and maintenance therapy: 1 capsule of Broncho-Vaxom® adult daily in the morning on an empty stomach. The course includes 3 cycles, each of which consists of taking 1 capsule daily for 10 days, the interval between the cycles is 20 days.

If the capsule is difficult to swallow, open it and mix the contents with a drink (including fruit juice, milk).

Interaction

Broncho-Vaxom® Adult can be used simultaneously with other medicinal products for the treatment of acute and chronic respiratory diseases.

The drug interaction of Broncho-Vaxom® Adult with other medicinal products has not yet been established.

Special Instructions

There is no need to take precautions when using the drug.

Impact on driving and operating machinery

Broncho-Vaxom® Adult does not affect the ability to drive vehicles and operate machinery.

Contraindications

Hypersensitivity to the components of the drug.

On the basis of available information it is not recommended to prescribe to children under 6 months of age due to the immaturity of their immune system.

In order to avoid overdose, children should not take the product from capsules intended for adults.

Side effects

Broncho-Vaxom® adult is usually well tolerated. The results of clinical studies indicate that the incidence of mild adverse reactions is 3-4%.

Digestive system disorders: nausea, abdominal pain, vomiting.

Dermatological reactions: itching, erythema.

Respiratory system: cough, shortness of breath.

Nervous system disorders: headache, feeling of fatigue.

In case of continuing gastrointestinal disorders, skin reactions and respiratory manifestations, the drug should be stopped, because they may be allergic reactions. In such a situation, the patient should consult with their physician.

Overdose

There are no reports of overdose.

The nature of the drug Broncho-Vaxom® adult and the results of its toxicity study indicate that overdose is unlikely.

Pregnancy use

The use of the drug Broncho-Vaxom® adult in pregnancy and lactation is possible when the expected benefits to the mother exceed the potential risk to the fetus or infant.

There have been no clinical studies of the drug in pregnant women.

There have been no specific studies on the safety of the drug during breastfeeding and no data are available at this time.

There have been no negative effects on pregnancy, embryo, fetal and/or postnatal development in experimental animal studies.

Similarities